Analyst Price Target Update on OraSure Technologies (NASDAQ:OSUR)

OraSure Technologies (NASDAQ:OSUR): 2 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $8.25 in OraSure Technologies (NASDAQ:OSUR). However, the stock price could fluctuate by $ 0.35 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $9 price target with the lower price estimate is calculated at $8

For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities,The director officer (COO & CFO) of Orasure Technologies Inc, Spair Ronald H sold 75,974 shares at $10.01 on December 19, 2014. The Insider selling transaction had a total value worth of $760,500. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

OraSure Technologies (NASDAQ:OSUR) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.95 points or 12.21% at $6.83 with 1,712,107 shares getting traded. Post opening the session at $7.4, the shares hit an intraday low of $6.67 and an intraday high of $7.5 and the price was in this range throughout the day. The company has a market cap of $379 million and the number of outstanding shares have been calculated to be 55,483,238 shares. The 52-week high of OraSure Technologies (NASDAQ:OSUR) is $7.99 and the 52-week low is $4.39.

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test, OraQuick ADVANCE, OraSure HIV-1 oral specimen collection device, OraQuick HCV rapid antibody test, Intercept oral fluid drug testing system, OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary, DNA Genotek Inc., the Company provides oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *